Advanced Cancers
87
5
8
52
Key Insights
Highlights
Success Rate
79% trial completion
Published Results
23 trials with published results (26%)
Research Maturity
52 completed trials (60% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 59/100
16.1%
14 terminated out of 87 trials
78.8%
-7.7% vs benchmark
5%
4 trials in Phase 3/4
44%
23 of 52 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 52 completed trials
Clinical Trials (87)
The Effects of Ginseng on Cancer-Related Fatigue
Clinical Trial of TQB2922 Injection (Subcutaneous Injection) in Patients With Advanced Cancers
Haloperidol and Lorazepam for Delirium in Patients With Advanced Cancer
Psilocybin in Cancer Pain Study
Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies
Personalized Oncogenomics (POG) Program of British Columbia
Temsirolimus in Combination With Metformin in Patients With Advanced Cancers
A Multicenter, Open Label Phase I Clinical Trial Evaluating the Safety and Pharmacokinetics of TQB2252 Injection in Subjects With Advanced Malignant Tumors
A Clinical Study of TQB3107 Tablets in Patients With Malignant Tumors
Hepatic Impairment Study for Lorlatinib in Cancer Patients
Plasmodium Immunotherapy for Advanced Cancers
A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies
Clinical Trial of the TQB3602 Capsule Combined With AK105 Injection in Patients With Advanced Cancers
Phase II Study of Ilorasertib (ABT348) in Patients With CDKN2A Deficient Solid Tumors
Fentanyl Pectin Nasal Spray (FNPS) for Exercise-Induced Breakthrough Dyspnea
Cordotomy for Refractory Cancer Pain
Dasatinib and Crizotinib in Advanced Cancer
Pazopanib and Everolimus in PI3KCA Mutation Positive/PTEN Loss Patients
A Study of LY2606368 (Prexasertib) in Patients With Solid Tumors With Replicative Stress or Homologous Repair Deficiency
MLN9708 and Vorinostat in Patients With Advanced p53 Mutant Malignancies